On Dec. 2, the Centers for Medicare and Medicaid Services (CMS) issued a Request for Information (RFI) on Essential Health Benefits (EHB). The RFI sought input on a proposed switch to the U.S. Pharmacopeia Drug Classification (USP DC) standard for defining the EHB prescription drug category. AMCP's comments, submitted on Jan. 31, urge CMS to refrain from switching to any alternative prescription drug classification standard.
AMCP's volunteers are vital players in propelling our mission forward. In this installment of the AMCP Volunteer Spotlight, we are featuring Brenden O'Hara, RPh, BCACP, Carolinas AMCP President, Diplomat, and Professional Practice Committee member.
On Dec. 21, the Department of Health and Human Services released a proposed rule titled "Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024." On Jan. 30, AMCP submitted comments which oppose two issues from the proposed rule; continuing formulary tier limitations for standardized plan options and new limits on the number of non-standardized plan options that issues may offer through the federal Marketplace.
On Jan. 27, AMCP, along with 76 other healthcare organizations, signed on to a consensus statement on health equity. In the statement, signatories recognize health inequity as a complex issue and reaffirm their commitment to take action within their organizations to reduce health inequities for the broader population.
This webinar featured a candid conversation with panelists from AMCP’s Market Insights Roundtable on Optimizing the Management of Inherited Blood Disorders. Speakers will provide an overview of the current and evolving coverage and treatment landscapes for Hemophilia, Sickle Cell, and Beta Thalassemia.
This webinar featured a candid conversation with panelists from AMCP’s Market Insights Roundtable on The Role of BTKi’s in the Management of CLL. Speakers will provide an overview of the current and evolving coverage and treatment landscapes for managing CLL.
This sponsored webinar aims to understand the evolution of the treatment landscape, goals of treatment, and managed care considerations in Chronic Lymphocytic Leukemia (CLL) and to provide an update on the new clinical and health-economic data for Venclexta® (venetoclax) in the treatment of patients living with CLL.
